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Accuracy of the diagnosis of hypertensive nephrosclerosis in African
Americans: A report from the African American Study of Kidney Disease
(AASK) Trial. African Americans have excess hypertension and end-stage
renal disease presumed due to hypertension compared to Caucasians. The
AASK was designed to examine the impact of antihypertensive therapies
and two levels of blood pressure control on the rate of decline of GFR in
African Americans with presumed hypertensive renal disease. During the
pilot phase of the trial, eligible participants were requested to undergo
renal biopsy to assess the underlying lesions in this population. Eighty-
eight hypertensive (diastolic BP > 95 mm Hg) non-diabetic African
American patients between the ages of 18 to 70 years, with GFR between
25 to 70 ml/min/1.73 m2 and without marked proteinuria were assessed for
possible renal biopsy. Forty-three patients did not undergo renal biopsy
due to refusal or contraindications. Adequate renal biopsies were ob-
tained in 39 of the remaining 46 patients. Biopsy findings were analyzed
and then compared to clinical parameters. The 39 patients studied, 29 men
and 10 women, were on average 53.0 11.0 years old, and had a MAP of
109 15 mm Hg and GFR 51.7 13.6 ml/min/1.73 m2 (not significantly
different from nonbiopsied patients). Thirty-eight of these 39 biopsies
showed arteriosclerosis and/or arterioloselerosis, severity on average 1.5
0.9 and 1.5 0.8, respectively on a 0 to 3+ scale. Interstitial fibrosis was
moderate, 1.3 0.9 (0 to 3+ scale). Segmental glomerulosclerosis was
present in five biopsies, and in one patient, biopsy and clinical findings
were consistent with idiopathic focal segmental glomerulosclerosis. Addi-
tional lesions included mesangiopathic glomerulonephri(is in one patient,
basement membrane thickening suggestive of diabetic nephropathy in
one, and cholesterol emboli in two eases. Arteriolar and arterial sclerosis
were tightly linked, and correlated with interstitial fibrosis and the
reciprocal of serum creatinine. Global glomerulosclerosis was extensive,
involving on average 43 26% of glomeruli. The extent of this lesion did
not correlate with degree of arteriolar or arterial thickening, but did
correlate with systolic blood pressure (P = 0.0174), the reciprocal of
serum creatinine (P = 0.0009), serum cholesterol (P = 0.0129) and
interstitial fibrosis (P < 0.0001). These data underscore that renal biopsies
in non-diabetic hypertensive African-Americans with mild to moderate
renal insufficiency in the absence of marked proteinuria are overwhelm-
ingly likely to show renal vascular lesions consistent with the clinical
diagnosis of hypertensive nephrosclerosis.
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Hypertension is a major problem in the United States affecting
approximately 60 million people. It is associated with significant
morbidity and mortality due both to cardiovascular and renal
diseases [1, 2]. End-stage renal disease (ESRD) attributed to
hypertensive nephrosclerosis is a leading cause of ESRD in
African Americans [3, 4]. Although African Americans make up
only 12% of the U.S. population, 28% of patients on hemodialysis
are African Americans, and the rate of developing ESRD is four
times greater for African Americans than for Caucasians [5, 6].
Further, 41% of patients newly admitted to ESRD programs with
a clinical diagnosis of hypertensive nephrosclcrosis arc African
American. The increased susceptibility to renal failure in African
American hypertensive patients 17—13] is not accounted for solely
by higher prevalence of hypertension [14, 15], severity of hyper-
tension or by socioeconomic factors [16].
The assumption that end-stage renal disease is due to hyper-
tension in this population has largely been derived from ESRD
registries which use clinical diagnoses unsubstantiated by biopsy
or autopsy data [6, 17]. However, primary renal diseases other
than hypertensive nephrosclerosis are present in at least some
patients who also have coexistent hypertension [18]. Thus, the
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true incidence and prevalence of ESRD secondary to hyperten-
sion may have been overestimated. Such a misclassification bias
might be exaggerated in African Americans compared with Cau-
casians [191. In the African American Study of Kidney Disease
and Hypertension (AASK) Pilot Study, African American hyper-
tensive patients with moderately reduced renal function were
randomized to one of two levels of blood pressure control and to
one of three antihypertensive drug regimens to determine optimal
antihypertensive therapy in this patient population. Prior to
randomization, renal biopsies were performed on eligible partic-
ipants. The objectives of this biopsy study were to define renal
structural abnormalities in African Americans with a diagnosis of
hypertensive nephrosclerosis, based on strict clinical criteria.
Methods
Patient population
The design, recruitment experience, baseline characteristics of
study participants, and adherence to the study protocol in the
AASK trial have been previously reported [20, 21]. Patients were
eligible for this study if they were African American, between 18
and 70 years of age, and had hypertension, defined as diastolic
blood pressure  95 mm Hg. Patients were also required by entry
criteria to have mild to moderate renal insufficiency, defined as
iothalamate glomerular filtration rate between 25 and 70 mI/min/
1.73 m2 [22]. Patients showed absence of marked proteinuria, with
urine protein/creatinine ratio 2.0, determined by a 24-hour
urine collection during the baseline period. Eligible patients had
no clinical evidence of immune complex disease or of diabetes
mellitus. Contraindications to renal biopsy defined in the study
protocol were: blood pressure > 140/90 mm Hg immediately
before biopsy; an abnormal prothrombin time, partial thrombo-
plastin time, platelet count, bleeding time or history of bleeding
diathesis; inability to withdraw aspirin or NSAIDs for 10 days
before and following the renal biopsy; hematocrit <25%; unco-
operative participant or a patient unwilling to undergo a blood
transfusion; the presence of a solitary kidney, urinary tract
infection, pregnancy, renal or other anatomic abnormality that
would increase the risk of the procedure; obesity (kidneys located
at> 10 cm depth from the flank surface); and longitudinal kidney
size < 9 cm estimated by renal imaging. Forty-nine patients were
not biopsied for the study either because of unwillingness (N =
23), contraindication to biopsy (N = 19), or a previous renal
biopsy (N = 7). Renal biopsies were performed during the
baseline period of the study in 46 of the 95 participants, with 39
biopsies yielding adequate tissue for interpretation.
Following the renal biopsy, patients were then randomized in
antihypertensive treatments [atenolol (ICI Zeneca, Wilmington,
DE, USA), amlodipine (Pfizer Inc., New York, NY, USA), or
enalapril (Merck & Co., West Point, PA, USA)1.
Renal biopsy analysis
All biopsies were performed at the participating medical cen-
ters. Attempts were made to obtain two cores of tissue which was
divided, placed in appropriate fixatives and sent to the central
laboratory for routine processing. Tissue for light microscopy was
serially sectioned, with three sets each consisting of three consec-
utive slides stained with hematoxylin and eosin, periodic acid-
Schiff, and Jones' stains. Tissue in Michel's fixative was frozen and
stained with antisera to immunoglobulins G, A, M, C3, and C4,
and examined by fluorescence microscopy. Material for electron
microscopy was routinely processed, and thin sections were exam-
ined by a renal pathologist.
All biopsies were coded with a patient acronym and were
assessed without knowledge of the patient's age, gender, or any
clinical parameters. The presence of global or segmental glomer-
uloscierosis was assessed and quantified as percent of glomeruli
involved with sclerosis. Interstitial fibrosis, arteriolar thickening,
and arterial thickening were scored semiquantitatively on a 0 to
3+ scale, with 0 no lesions present, 1 + mild abnormality, 2+
moderate, and 3+ severe. Immunofluorescence positivity was
noted and specified according to location and intensity of staining
on a 0 to 3+ scale. Electron microscopy studies analyzed glomer-
uli for additional evidence of abnormalities.
One set of three biopsy slides was subsequently sent to the
designated pathologist at each clinical center for clinicopathologic
interpretation. All slides were then returned, collected, and
reviewed by the three member biopsy task force. To avoid bias
resulting from knowledge of the clinical setting as defined by
AASK entry criteria, additional renal biopsy slides from 11
non-AASK cases with diverse diagnoses, including glomerulone-
phritides, interstitial nephritis and vascular disease were included
for review. All slides were labeled with consecutive code numbers
so as to mask the origin of the cases, that is, whether they were
from AASK or non-AASK biopsies. The slides were initially
scored blindly by the two additional members. The code was then
broken, and AASK cases reviewed in view of clinical information.
Results from the non-AASK biopsies were in agreement with the
original diagnoses. Results from the review of AASK cases by all
three renal pathologists with and without clinical information are
presented.
Statistical analysis
Paired associations between individual selected variables and
the pathology descriptors were evaluated using Spearman corre-
lation coefficients or contingency table tests of independence, as
appropriate. Multiple stepwise regression with backward elimina-
tion was used to evaluate the relationships between glomerulo-
sclerosis, and gender, body mass index, age at first contact,
smoking history, systolic and diastolic blood pressure, reciprocal
of serum creatinine, eligibility GFR, the common logarithm of
urinary protein excretion, the urine protein to creatinine ratio,
serum cholesterol and the duration of hypertension. Segmental
sclerosis was present only rarely and with limited dispersion, and
was therefore recoded as a dichotomous variable, and analyzed
using multiple logistic regression. Cumulative multiple logistic
regression was used for variables which represented rank ordered
scales, that is, interstitial fibrosis, arteriolar thickening and arterial
thickening. Comparisons of the clinical and demographic charac-
teristics of biopsied participants with those randomized, but not
hiopsied, were performed using multiple logistic regression. Re-
sults are presented as mean SD.
Results
Patient population
Of the 7 patients with previous renal biopsies, 4 of these were
available for review. These previously biopsied patients had lower
GFR than patients with biopsy attempted for the study; 33.8 3.9
versus 51.1 13.9 ml/min/1.73 m2. The diagnoses were apparent
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Table 1. Baseline demographic and functional characteristics
Age
years
Gender
M/F
MAP
mm Hg Uprotjr
GFR
mI/mini]. 73 m2
Biopsies attempted (N = 46) 53.7 10.6 37/9 109 14 0.31 0.6 51.1 13.9
Adequate biopsies (N = 39) 53.0 11.0 29/10 109 15 0.33 0.7 51.7 13.6
Nonbiopsied (N = 42) 54.8 11.0 31/11 109 17 0.34 0.7 53.5 14.0
Data are shown as mean SD. Abbreviations are: MAP, mean arterial pressure; Uproticr, urine protein/creatinine ratio.
focal segmental glomeruloscierosis in two, one case of mesangio-
pathic glomerulonephritis, and one case with only vascular scle-
rosis. These biopsies were performed due to different clinical
indications than those biopsies performed for this study, and are
therefore not included in subsequent analyses presented here.
The initial evaluation without clinical information was com-
pared with subsequent morphologic evaluation by the three-
member panel. Review of biopsies by all three panel members
resulted in recategorization from the initial reading of severity of
lesions as follows: in one case, vascular lesions were decreased one
grade; in two cases, increased one grade; and, in one case, early
segmental adhesion of the glomerulus, an early sign of glomeru-
losclerosis, was added. Results from the panel consensus are
presented.
Patients with renal biopsies attempted for this study included 37
men and 9 women. Clinical parameters were not significantly
different in biopsied versus nonbiopsied patients (Table 1).
Eighty-nine percent (41 of 46) of patients had no complications
from renal biopsy. Three patients developed gross hematuria that
subsided spontaneously within days. One patient had more pro-
nounced bleeding (> 4 percentage points drop in hematocrit) that
subsided spontaneously with no change in renal function (serum
creatinine 1.6 to 1.8 mg/dl at prebiopsy visits; 1.7 mgldl at
postbiopsy visit). One patient required blood transfusion when the
hematocrit decreased from 39% to 33%. Serum creatinine in-
creased from 3.6 mg/dl at baseline to a maximum of 5.5 mg/dl two
days after the bleed. An arteriogram with embolization of a
pseudoaneurysm was performed, and the patient recovered with
serum creatinine returning to baseline within one month after
discharge.
Biopsy findings
The 39 adequate biopsies contained, on average, 11.5 glomeruli
(range 3 to 34). Tissue for immunofluorescence (IF) was available
in 34 of the 39 cases (87.2%). Tissue with glomeruli for electron
microscopic (EM) evaluation was available in 33 of the 39 samples
(84.6%). Thirty-seven of the 39 biopsies had either IF or EM or
both performed. Therefore, in three cases, EM but not IF
examination was available and, in 4 cases, IF but not EM was
available.
Thirty-eight cases showed the presence of arteriolosclerosis
and/or arteriosclerosis (Table 2, Fig. 1). Arteriolar thickening was,
on average, 1.5 0.9 (0 to 3+ scale), with comparable arterial
thickening, 1.5 0.8. Hyaline deposits in arterioles and/or arteries
were present in over half of the biopsies (56%). Intimal fibrosis of
medium sized arteries was detected in 62% of cases, with occa-
sional proliferation (4 cases) or more frequently atrophy (12
cases) of the tunica media. Interstitial fibrosis was also moderate,
on average, 1.3 0.9 (0 to 3+ scale). One biopsy showed end
stage disease.
Table 2. Biopsy lesions
Severity of vascular lesion
Mild Moderate Severe Total
Arterioloscierosis 10 15 8 33
arteriosclerosis
Arteriolosclerosis 3 1 1 5
arteriosclerosis +
segmental glomerulosclerosis
Additional lesions
Global glomerulosclerosis 35
Segmental glomerulosclerosis 5
End stage kidney 1
Mesangiopathic glomerulonephritis 1
GBM thickening 1
Cholesterol embolus 2
Abbreviation is: GBM, glomerular basement membrane
The biopsies revealed a high level of global glomerular sclerosis
involving, on average, 43 26% of glomeruli, substantially
greater than expected for this age group (—17% for age 54 years)
(Fig. 2) [23—26]. One small biopsy showed only global glomerular
sclerosis without vascular lesions detected, while only 4 biopsies
showed no global glomeruloselerosis. Segmental glomerular scle-
rosis was present in S cases (3%). Four of these biopsies also
showed presence of hyalinosis, the remaining case showed only
small synechiae. Hyalinosis was present in globally sclerotic
glomeruli in six additional cases.
Five biopsies showed either only synechiae (one case) or focal
segmental glomerulosclerosis (FSGS) associated with arteriolar
and arterial sclerosis and global sclerosis (four cases). Electron
microscopy was available in 4 of these 5 patients. In three of these,
minimal foot process fusion (10 to 25%) was present. After review
of clinical information, the diagnosis of idiopathic FSGS was
further not supported due to lack of significant proteinuria in four
of the five patients (Uprot 36, 36, 78 and 539 mg/24 hr; GFR 40,
51, 36, and 66 ml/min!1.73 m2, respectively). In one patient,
clinical and morphologic findings were consistent with idiopathic
nephrotic syndrome with FSGS. This patient had 3 g/24 hr
proteinuria and GFR of 56 ml/min/1.73 m2, and extensive foot
process effacement. Conversely, in 5 other patients with protein-
uria  I g/24 hours, no specific lesions other than global glomer-
ulosclerosis and arteriolar and arterial nephrosclerosis were
present. Electron microscopic evaluation showed intact foot pro-
cesses in most cases without segmental sclerosis, with minimal
foot process effacement (< 10%) present in 3, and --10 to 20%
foot process effacement in only one of these cases.
Additional lesions included cholesterol emboli in two eases, and
glomerular basement membrane thickening in one biopsy, highly
suggestive of diabetic nephropathy (GBM thickness average 550
nM, range 514 to 607 nM, Fig. 4). This patient is a 48-year-old man
tr a
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Fig. 1. Arterial (A) and arteriolar (B) lesions.
Medial thickening is evident in the artery. The
arteriole shows marked intimal proliferation
(Jones' silver stain, ><400).
with only minimal proteinuria (57 mg/24 hr), GFR 47 ml!min/1.73
m2 and serum creatinine 2.0 mg/dl. Repeated blood glucose
determinations have been within normal range. One biopsy
revealed mesangial dense deposits by electron microscopy and
mild increase in mesangial matrix by light microscopy in addition
to mild arteriolosclerosis (Fig. 3). Immunofluorescence was not
available on this case; however, the morphologic findings are
consistent with IgA nephropathy. The patient is a 47-year-old man
with 62 mg124 hr of proteinuria, GFR 25 ml/min/1.73 m2, and
serum creatinine of 3.3 g/dl. He has not had hematuria, signs of
Henoch-SchOnlein purpura, and does not have a family history of
renal disease.
Correlations of moiphologic and clinical parameters
Analyses of interrelationships of these morphologic parameters
showed significant correlations of interstitial fibrosis and global
glomerulosclerosis (r = 0.6888, P < 0.0001). There was also tight
correlation of arteriolosclerosis and arteriosclerosis (r = 0.7030,
P < 0.0001). Both arteriolosclerosis and arteriosclerosis then
correlated with interstitial fibrosis (r = 0.5714, P < 0.0001 for
arteriolosclerosis; r = 0.3919, P = 0.0136 for arteriosclerosis).
Surprisingly, arteriolosclerosis and arteriosclerosis did not corre-
late significantly with the percent of glomeruli involved with
global glomerulosclerosis (r = 0.3046, r = 0.1837 for arteriolo-
sclerosis and arteriosclerosis, respectively, vs. global sclerosis, P =
NS). Biopsy lesions were also correlated with clinical parameters
(Table 3). Global glomerulosclerosis correlated significantly with
systolic blood pressure, the reciprocal of serum creatinine, and
with serum cholesterol (Table 3). No correlation of global gb-
merulosclerosis with either age, gender, body mass index, smoking
history, baseline GFR, known duration of hypertension, protein-
uria or urine protein to creatinine ratio was present by multiple
regression analysis. The few patients with segmental sclerosis
tended to be younger than the patients without this lesion (P =
0.036). An unexpected finding was the positive correlation of
younger age with more severe interstitial fibrosis. Interstitial
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Fig. 2. Severe global glomerulosclerosis and
patchy interstitial fibrosis and tubular atrophy are
evident. An interlobular size artery shows
marked medial thickening (Jones' silver stain,
x120).
fibrosis was the only morphologic parameter that correlated with
the degree of proteinuria. The severity of vascular lesions corre-
lated with the reciprocal of serum creatinine, as did interstitial
fibrosis. The multiple regression model indicates the significance
of three variables, namely, systolic blood pressure, reciprocal of
serum creatinine and cholesterol, in predicting the percent of
globally selerosed glomeruli. Of note, the reciprocal of serum
creatinine is a stronger predictor of renal pathology than GFR in
all analyses. That relationship can be expressed mathematically:
[percent glomeruli globally sclerosed =
— 7.21 + 0.36 x systolic blood pressure
93.8 X (l/Scr) + 0.20 X serum cholesterol].
Thus, when all three variables are considered, the percentage of
globally sclerosed glomeruli increases 3.6 percentage points for
each 10 mm Hg increase in systolic blood pressure. The percent-
age of globally sclerosed glomeruli increases 9.38 percentage
points for each 0.1 decrease in the reciprocal of serum creatinine
and increases 2 percentage points for every 10 mgldl increase in
serum cholesterol. The analysis indicates that the reciprocal of
serum creatinine is the strongest of the three variables in predict-
ing percent of glomeruli globally sclerosed, whereas systolic blood
pressure and serum cholesterol levels have equal importance in
predicting extent of global glomerular sclerosis.
Discussion
This study confirms that renal biopsies in non-diabetic hyper-
tensive African-Americans with mild to moderate renal insuffi-
ciency in the absence of nephrotic range proteinuria are over-
whelmingly likely to show morphological lesions consistent with
hypertensive nephrosclerosis. These changes typically consist of
vascular wall medial thickening with frequent arteriolar hyaline
deposits, varying degree of intimal fibrosis and focal glomerular
ischemic changes with variable thickening and wrinkling of the
basement membrane, tubular atrophy and interstitial fibrosis [27,
28]. Some foot process effacement may also be present [29].
Although none of these lesions is pathognomonic, the constella-
tion of these changes in the absence of other lesions of primary
glomerular disease is indicative of hypertensive nephrosclerosis.
In this study, these changes of hypertensive nephrosclerosis were
widespread in nearly all cases. The severity of global glomerulo-
sclerosis was an unexpected finding in this African American
population. The extent of global glomerulosclerosis correlated
with the degree of hypertension, and the extent of global glomer-
ulosclerosis, arteriolar and arterial wall thickening, and interstitial
fibrosis all correlated with the degree of renal insufficiency.
Although marked proteinuria was an exclusion criterion in this
pilot study, six newly biopsied patients had > 1 g/24 hr protein-
uria. One of these patients showed morphological lesions consis-
tent with FSGS, whereas no specific glomerular lesions were
present in the remaining five patients, consistent with previous
studies [30—32]. The presence of marked proteinuria in patients
with apparent hypertensive nephrosclerosis has been suggested as
a poor prognostic sign [30]. In one small retrospective study, the
development of nephrotic syndrome in patients with nephroscle-
rosis on renal biopsies indeed was associated with a poor prog-
nosis [32]. Significant proteinuria in the absence of specific lesions
on renal biopsy has been reported in 6% of patients in one biopsy
series from the United Kingdom [33]. In our prospective study,
long-term follow-up is not yet available to assess potential impact
of proteinuria on clinical course.
The extent of arterio- and arteriolosclerosis did not correlate
with age at first contact in this study, supporting that a disease
process rather than aging per se contributed to the changes.
However, it is possible that too narrow a range of ages was
represented in this study to detect such a trend. Attempts to
establish "normal aging" changes have largely relied on studies of
autopsies, excluding cases with cardiovascular disease. In one such
study, vessel wall thickening increased only marginally in the adult
African American group up to age 44 years, but doubled in the
next decade [34]. Lesions also increased with age, but were less
severe, in the Caucasian population. These studies suggest that
vascular thickening accompanies aging even in the absence of
overt cardiovascular disease. Extrapolation from blood pressure
Fig. 3 . Mecangia! dense de,,acits n'ere present in one biopsy (tronsmi.ssio;: eleciro,, nzierogruph xS300).
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i . sangial dense depo its were present in one biopsy (transmission electron micrograph, X5,300).
Fig. 4. The glomerular basement membrane was significantly thickened in one case (range 514 to 607 nm) (transmission electron micrograph, X 7,000).
data from other studies interestingly suggested that higher blood
pressure in the African American population did not completely
account for the greater vascular wall thickening in this population
compared to Caucasians [35].
Hypertension is presumed to cause end organ damage. In a
large series of renal biopsies in patients with essential hyperten-
sion, arteriolar nephrosclerosis was present in 81.2%, and the
severity of arteriolar sclerosis correlated significantly with level of
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Table 3. Clinicopathologic correlations
Extent
global
glomerulosclerosis
Severity
arteriolo-,
arteriosclerosis
Severity
interstitial
fibrosis
Higher systolic BP P = 0.0174 MS NS
Lower 1/5Cr P = 0.0009 P = 0.0031,
P = 0.0173
P = 0.0904
Higher Upr,i NS NS P = 0.0073
Higher cholesterol P = 0.0129 NS NS
Younger age NS NS P = 0.0310
Abbreviations are: BP, blood pressure; 5Cr' serum creatininc; Uprot,
proteinuria; NS, not significant.
diastolic blood pressure [36]. However, in several large autopsy
series of patients with presumed benign hypertension, significant
renal lesions were rare [37, 38]. Despite evidence for a salutary
effect of antihypertensive treatment in Caucasian hypertensive
patients, studies in hypertensive African Americans have not
consistently shown a benefit of blood pressure control on progres-
sion of renal disease [39, 40]. These findings point to the
possibility of unrecognized primary renal disease in this popula-
tion. The current study indicates that immune complex glomeru-
lonephritis is not present in these patients, except very rarely.
Whether vascular, glomerular or interstitial lesions account for
the initiation of renal insufficiency remains unclear. The findings
do not exclude the possibility that a primary renal microvascular
disease results in both hypertension and global glomerulosclerosis
[411. The high prevalence of extensive global glomeruloscierosis in
this study may relate to previously unrecognized pathogenic
processes in this population [42]. Global sclerosis may normally be
present in I to 3% of glomeruli in adult patients up to —50 years
old [24, 25]. The extent of global sclerosis number increases with
advanced age, up to 30% by age 80 years [25]. Globally sclerosed
glomeruli in greater percentage have been taken to indicate
underlying renal disease (focal global sclerosis) [261. In previous
studies of hypertensive nephrosclerosis, varying degrees of global
sclerosis have been described. Global glomerular sclerosis ranged
from 4 to 24%, largely within expected range for age, among eight
adult patients (average age 48 years, ethnic origin not specified)
with benign essential hypertension and hyaline arteriosclerosis on
biopsy [29]. In a study of elderly Japanese patients with hyperten-
sion only minimal global glomerulosclerosis was present. Mild to
severe intimal proliferation with iritimal fibrosis was present in
arteries in all patients, while arterioles were unremarkable [43]. In
Japanese patients with benign nephrosclerosis, intimal thickening
of small arteries, but not large, correlated with extent of glomer-
ulosclerosis [44]. A retrospective series from the United Kingdom
of renal biopsies in 27 patients with hypertension and protcinuria,
revealed immune complex glomerulonephritis in six, and segmen-
tal sclerosis in eight. Global glomerulosclerosis was present in on
average 30% of glomeruli in those without other glomerular
abnormalities, and iii 40% of glomeruli in those with other
glomerular changes [45]. These observations point to possible
differences between populations, both in "normal" aging and in
response to injury.
Not only is the occurrence of hypertension and apparent
associated renal disease much more common in African Ameri-
cans than in Caucasians, familial clustering of chronic renal failure
has been noted in African Americans [46, 47]. These and other
observations have led to investigation of genetic factors contrib-
uting to differences in susceptibilities to disease among population
groups. Of special relevance to hypertensive end organ damage
are recent results relating to genes for the renin-angiotensin
system. Angiotensin II in addition to vasoconstrictor effects,
promotes mesangial and vascular smooth muscle cell growth and
matrix production, which impact sclerosis of vessels and glomer-
uli. Specific polymorphisms in angiotensin converting enzyme
(ACE), angiotensinogen and the angiotensin type 1 receptor
genes have been linked with cardiovascular disorders, including
hypertension, myocardial infarction and cardiac hypertrophy [48].
Angiotensinogen gene mutations were increased in African
Americans with essential hypertension, compared to Caucasian
hypertensive populations [49]. An insertion deletion (lID) poly-
morphism of the ACE gene has also been studied extensively. The
DD genotype is significantly more frequent in African American
populations compared to Caucasians [50, 51]. Several patient
populations, including Caucasians and Japanese, showed signifi-
cantly greater incidence of progression of renal disease in those
who were homozygous for the D polymorphism compared to
other patients [52, 53]. The D polymorphism may affect renin-
angiotensin system activity and response to ACE inhibitors [53—
561. The decrease in proteinuria in response to ACEI is more
pronounced in patients with DD genotype, independently of an
antihypertensive effect. This polymorphism could therefore affect
response to injury and treatment in hypertensive nephrosclerosis.
Whether these effects of the ACE polymorphism are also present
in the African American population has not been determined.
Previously, we investigated possible structural differences be-
tween normal African American and Caucasian populations at
autopsy. Glomerular volume was significantly greater in African
Americans versus Caucasians, and the distribution pattern was
different in the two groups. The African American population
showed a Gaussian distribution of glomerular size, whereas the
Caucasian population had a bi-modal distribution, with a sub-
group with enlarged glomerular size comparable to that in the
African American population [57]. Decreased nephron number at
birth, linked to low birth weight, has been suggested to underlie
increased risk for progressive renal disease [58]. However, recent
data suggest that low birth weight follows other factors more
closely than racial origin [59]. An additional hypothesis is based
on the finding that the renin-angiotensin system modulates mat-
urational glomerular growth in animal models [601. Whether
altered genotypes for renin-angiotensin may affect glomerular
development and subsequent response to injury remains to be
elucidated. In this regard, modulation of the renin-angiotensin
system by chronic ACE inhibitor treatment decreased matrix
expansion and thickening associated with aging in glomeruli and
blood vessels [61—64].
In summary, the clinical diagnosis in African Americans of
hypertensive nephrosclerosis based on careful clinical and labo-
ratory evaluation is highly accurate. The incidence of other
glomerulonephritides in patients thus defined clinically is exceed-
ingly low. The pathogenesis of the severe global glomerular
sclerosis in this population remains undefined. Whether the
severe global glomerulosclerosis observed in this study is related
to abnormal acceleration of aging, or separate pathogenetic
mechanisms, has not been established. Further investigation of
genetic markers, follow-up, and prospective evaluation will be
4ASK Trial: Hypertensive nephrosclerosis in African Americans 251
necessary to define the mechanisms underlying the full spectrum
of structural lesions in this population.
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